Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;9(1):1-3.
doi: 10.5114/pg.2014.40842. Epub 2014 Mar 1.

Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

Aldona Mularczyk  1 , Maciej Gonciarz  1 , Witold Bartnik  2 , Marek Durlik  3 , Piotr Eder  4 , Anita Gąsiorowska  5 , Krzysztof Linke  4 , Michał Lodyga  6 , Liliana Lykowska-Szuber  4 , Ewa Małecka-Panas  5 , Magdalena Pawlik  6 , Piotr Radwan  7 , Grażyna Rydzewska  8
Affiliations

Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

Aldona Mularczyk et al. Prz Gastroenterol. 2014.

Abstract

Biological medical products are drugs whose active components are produced only by living, genetically modified organisms or live cell cultures. Patents and exclusivity for most biopharmaceuticals has either expired or will expire soon, which enables biotechnological companies to introduce similar biological products. The problem of replacing a biological medicine with a biosimilar in the course of therapy remains open. In this statement, the Working Group of the Polish National Consultant in Gastroenterology, in the absence of data regarding bioequivalence in patients with inflammatory bowel disease, does not recommend switching from original biological medicine to its biosimilar analogue in the course of treatment in inflammatory disease patients; however, this may change after receiving the results of controlled studies regarding bioequivalence in this group.

Keywords: biosimilar medicines; inflammatory bowel disease.

PubMed Disclaimer

References

    1. Walsh G. Second-generation biopharmaceuticals. Eur J Pharm Biopharm. 2004;58:185–96. - PubMed
    1. Available at: http://www.pharma.org/files/Biotech%202006.pdf/
    1. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals. 2012;5:353–68. - PMC - PubMed
    1. Lee JF, Litten JB, Grampp G. Comparabillity and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28:1053–8. - PubMed
    1. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8. - PubMed

LinkOut - more resources